Decline depth
-66.4%
From rolling 252-day high of $16.74, 359d ago.
Past the 40% Red List threshold.
-66.4%
from rolling 252-day high of $16.74 set 2025-05-20 · 359d ago
Current
$5.63
Decline depth
-66.4%
Decline σ
6.7σ
TFC
5/5 bearish
Rolling 252-day high
Up day
Down day
Last 90 trading days · data from Alpaca
Structural break signals
RXST qualifies for the Red List on decline depth.
Time-frame continuity
5/5 bearish
Latest bar across daily/weekly/monthly/quarterly/yearly time frames. A bar counts as bearish when it's a 2-Down or a red 3.
Full bearish continuity — every time frame is broken.
Decline sigma
6.7σ
Drop from local high over the last 20 bars, expressed in units of the stock's typical daily volatility (4.43% per day).
Past the ≥6σ Amber threshold.
The structural read
What price action says about RXST.
RXST qualifies for the Red List on decline depth — down -66.4% from its rolling 252-day high. Past the 40% threshold, the deepest tier in the taxonomy.
Cross-confirmation: also showing 5/5 bearish time frames.
Cross-confirmation: decline sigma also reads 6.7σ over 20 bars.
Earnings on file: 2026-02-25. Tiering is unaffected by earnings dates — listings reflect price structure only.
52-week range
52W low $5.90
0.0% of range
52W high $16.74
Sector context · Healthcare
182 other Healthcare tickers are on Broken Stocks.
92
Red List
43
Amber
47
Watch
-35.8%
Median decline
Worst in sector: OPRX (-76.7%). Least-bad: ANIP (-20.0%). See all Healthcare listings →
Related — same sector
Closest decliners to RXST
Red List
HIMS
Hims & Hers Health, Inc.
Red List
ATEC
Alphatec Holdings, Inc.
Red List
ARCT
Arcturus Therapeutics Holdings
Red List
QDEL
QuidelOrtho Corporation
Red List
WVE
Wave Life Sciences Ltd.
Red List Recovering
MLTX
MoonLake Immunotherapeutics
Questions about RXST
What people ask.
Why is RXST on Broken Stocks?
RXST qualifies for the Red List on decline depth. It is down -66.4% from its rolling 252-day high of $16.74, set on 2025-05-20 — 359d ago.
Is RXST a falling knife?
Not by the strict technical definition. RXST is down -66.4% from its 52-week high, but that high was set 359d ago — more than 120 days. A falling knife is usually a recent breakdown from a fresh high, not an established multi-quarter downtrend. RXST is still on the Red List for decline depth, but the freshness component of a falling knife is missing.
Is RXST a buy?
Broken Stocks does not issue buy or sell recommendations. The list is a rules-based technical warning system. It tracks structural decline depth and recency — not company quality, management, fundamentals, or news. Always do your own research and consult a licensed advisor.
Where is RXST trading inside its 52-week range?
At $5.63, RXST sits 0.0% of the way from its 52-week low ($5.90) to its 52-week high ($16.74). A reading below 25% indicates price is hugging the bottom of the range; above 75%, the top.
How fast has RXST been declining?
The current 66.4% decline accrued over 359d, which annualizes to roughly -67.5% per year. Annualized pace is a sanity check — a 30% decline in three months is a different signal than a 30% decline over two years.
How does RXST compare to its sector?
There are 182 other Healthcare tickers on Broken Stocks: 92 Red, 43 Amber, 47 Watch, with 55 showing recovering structural signals. Median sector decline is -35.8% — RXST's decline is deeper than the sector median.
Does RXST's earnings date affect its tier?
No. Tiering is decided purely by decline depth and recency of the rolling-high date. The earnings date on file (2026-02-25) is shown for reference only — listings can move tier between scans based on closing prices, regardless of fundamentals or news events.